View More Recent Stories
-
H.C. Wainwright Reiterates Neutral Rating on Sage Therapeutics (SAGE)
-
Scotiabank Reiterates Sector Outperform Rating on Sage Therapeutics (SAGE)
-
BofA Securities Reiterates Underperform Rating on Sage Therapeutics (SAGE)
-
TD Cowen Reiterates Buy Rating on Sage Therapeutics (SAGE)
-
Citi Reiterates Sell Rating on Sage Therapeutics (SAGE)
-
SAGE Therapeutics (SAGE) Announces Phase 2 SURVEYOR Study Reinforces Cognitive Impact of Huntington’s Disease

